Target intelligence / Profile preview

Vaccinia virus A33R protein (A33R)

Target
A33R
Molecular classification
Glycoprotein, Type II membrane protein, C-type lectin-like domain protein
01

Overview

The Vaccinia virus A33R protein is a highly conserved 23- to 28-kDa glycoprotein encoded by the A33R gene, forming a disulfide-bonded homodimer with N- and O-linked glycosylation. It is a type II transmembrane protein specifically incorporated into the viral outer envelope of extracellular enveloped virions (EEV), essential for efficient EEV formation, long-range viral spread, and cell-to-cell dissemination via actin tails. A33R provides chaperone function for A36R membrane localization and tyrosine phosphorylation, and coordinates incorporation of other proteins like B5 into EV membranes. Its ectodomain features an unusual C-type lectin-like domain (CTLD) structured as a flexible dimer similar to NK-cell receptor class CTLDs or Link modules, lacking a canonical carbohydrate-binding site but potentially binding viral or host ligands. Deletion mutants produce small plaques with comet tails, confirming its non-essential but critical role in replication. A33R is a target for neutralizing antibodies that recognize conformational epitopes.

Other names
A33 proteinOPG161
02

Mechanism of action

Neutralization of extracellular enveloped virus by binding conformational epitopes on A33 dimer, blocking viral spread

03

Biological functions

Viral envelope incorporationExtracellular enveloped virus formationCell-to-cell viral spreadChaperone for A36R protein traffickingActin tail formation
04

Disease associations

Infection
05

Interacting drugs

Anti-A33 monoclonal antibodies (A2C7, A20G2, A27D7)

Beyond the preview

Go deeper on Vaccinia virus A33R protein (A33R).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaccinia virus A33R protein (A33R).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call